A Drug & Medical Device Recall And/Or Safety Alert Has Been Issued: Xigris [drotrecogin alfa (activated)]: Market Withdrawal – Failure to Show Survival Benefit. According to the Food & Drug Administration FDA’s MedWatch:
In a recent study, Xigris failed to show a survival benefit for patients with severe sepsis and septic shock.
For more information on the drug or medical device recall or safety alert, read the Food & Drug Administration’s FDA’s drug or medical device recall or safety alert: Xigris [drotrecogin alfa (activated)]: Market Withdrawal – Failure to Show Survival Benefit.
To report an adverse reaction, problem or other issue with a drug or medical device, submit a drug or medical device complaint to the government at fda.gov or MedWatch.
If you have thoughts on the drug or medical device recall or safety alert, share your drug or medical device recall or safety alert comments below.